Is this the best healthcare stock money can buy after today’s update?

Should you buy this stock or a sector peer following today’s news?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Today’s interim results from Midatech (LSE: MTPH) have sent its shares down around 8%. While disappointing, this could present a buying opportunity and its performance and outlook provide clues about whether it’s the right time to buy it versus healthcare peers such as AstraZeneca (LSE: AZN), Hikma (LSE: HIK) and Smith & Nephew (LSE: SN).

Midatech’s first-half performance was upbeat. It was able to successfully integrate and deliver impressive sales performance from its recently acquired US commercial business. This helped it to grow sales by over 1,000% from £0.32m in the first half of 2015 to £3.8m in the first half of 2016. Furthermore, the launch of its anti-nausea product Zuplenz in the US in April has provided a boost to Midatech’s sales and this bodes well for its future performance.

In fact, Midatech is confident on its second-half outlook and in its longer-term prospects. It’s investing heavily in a number of R&D programmes as well as in platform technologies and candidate pipelines. They have the potential to turn Midatech from a lossmaking business to a profitable one over the long run. And with the company’s pre-tax losses set to narrow from £12m to £9m between 2016 and 2017, Midatech is moving in the right direction.

Lower risk?

However,Midatech remains a small and relatively high-risk buy. Therefore, other healthcare companies offer lower risk as well as high potential rewards. Among them is Smith & Nephew. It has a very stable business model owing to its dominant position within wound care and orthopaedics, both of which are more consistent arenas than pharmaceuticals. As such, Smith & Nephew has a low risk profile and with it due to increase earnings by 13% next year, it offers sound growth prospects too.

Hikma is also expected to record upbeat financial performance over the medium term. Its earnings are due to rise by 41% in the next financial year. This puts it on a lower price-to-earnings growth (PEG) ratio than Smith & Nephew, with its PEG being 0.5 versus 1.4 for Smith & Nephew. This indicates that Hikma offers significantly greater upward rerating potential, although with Hikma forecast to record a fall in its earnings of 23% this year, its financial performance is much more volatile than its sector peer.

Think long term

One healthcare stock that offers stunning long-term growth potential is AstraZeneca. Its bottom line has come under pressure due to patent losses, but it’s expected to return to positive growth over the medium term through its acquisition programme. Despite investing billions in its pipeline, AstraZeneca’s balance sheet and cash flow are strong and lower its risk profile significantly.

Alongside this is the potential to make further acquisitions to boost future growth. Due to this, AstraZeneca’s growth potential is hugely appealing even when compared to the likes of Hikma, Smith & Nephew and Midatech.

Furthermore, AstraZeneca yields 4.3% versus 1.9% for Smith & Nephew and 0.8% for Hikma, with Midatech paying no dividend. This means that as well as a low risk profile and strong growth potential, AstraZeneca has the most income appeal of the four stocks. So, despite being attractive, AstraZeneca is the most enticing of this healthcare quartet right now.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens owns shares of AstraZeneca. The Motley Fool UK has recommended AstraZeneca and Hikma Pharmaceuticals. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Bearded man writing on notepad in front of computer
Investing Articles

Could a 2025 penny share takeover boom herald big profits for investors?

When penny share owners get caught up in a takeover battle, what might happen? Christopher Ruane looks at some potential…

Read more »

Young woman working at modern office. Technical price graph and indicator, red and green candlestick chart and stock trading computer screen background.
Investing Articles

3 value shares for investors to consider buying in 2025

Some value shares blew the roof off during 2024, so here are three promising candidates for investors to consider next…

Read more »

Investing Articles

Can this takeover news give Aviva shares the boost we’ve been waiting for?

Aviva shares barely move as news of the agreed takeover of Direct Line emerges. Shareholders might not see it as…

Read more »

Investing Articles

2 cheap FTSE 250 growth shares to consider in 2025!

These FTSE 250 shares have excellent long-term investment potential, says Royston Wild. Here's why he thinks they might also be…

Read more »

A pastel colored growing graph with rising rocket.
Investing Articles

Has the 2024 Scottish Mortgage share price rise gone under the radar?

The Scottish Mortgage share price rise has meant a good year for the trust so far, but not as good…

Read more »

Investing Articles

Will the easyJet share price hit £10 in 2025?

easyJet has been trading well with rising earnings, which reflects in the elevated share price, but there may be more…

Read more »

Investing Articles

2 FTSE shares I won’t touch with a bargepole in 2025

The FTSE 100 and the FTSE 250 have some quality stocks. But there are others that Stephen Wright thinks he…

Read more »

Dividend Shares

How investing £15 a day could yield £3.4k in annual passive income

Jon Smith flags up how by accumulating regular modest amounts and investing in dividend shares, an investor can build passive…

Read more »